Myrtelle releases interim data from gene therapy trial for Canavan disease

Myrtelle has published interim results from its Phase 1/2 trial of the investigational gene therapy rAAV-Olig001-ASPA (MYR-101) in Nature Medicine, reporting changes in biomarkers, imaging and functional measures in children with Canavan disease, according to the company. The trial includes eight children with typical Canavan disease, followed for up to two years post-treatment. The company […] The post Myrtelle releases interim data from gene therapy trial for Canavan disease appeared first on Longevity.Technology.